Karyopharm Therapeutics Inc (NASDAQ:KPTI) finished Wednesday with an addition of $0.09 to close at $1.37, an upside of 6.61 percent. An average of 2,523,620 shares of common stock have been traded in the last five days. There was a gain of $0.1800 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 1,626,005 shares traded, while the 50-day average volume stands at 1,837,604.
KPTI stock has decreased by -0.72% in the last month. The company shares reached their 1-month lowest point of $1.1100 on 09/18/23. With the stock rallying to its 52-week high on 04/17/23, shares of the company touched a low of $1.11 and a high of $6.01 in 52 weeks. It has reached a new high 13 times so far this year and lost -59.71% or -$2.0300 in price. In spite of this, the price is down -77.20% from the 52-week high.
Insider Transactions
KPTI stock investors should be aware that Karyopharm Therapeutics Inc (KPTI) stock had its last reported insider trading activity 23 days ago on Sep 12. In this transaction, the insider spent $4,817. EVP & Chief Commercial Officer, Cheng Sohanya Roshan, disposed of 7,415 shares at a price of $1.33 on Sep 01. The insider now owns more than $9,872 worth of shares. Prior to that, EVP, CFO & Treasurer Mason Michael went on to Sale 6,913 shares at $1.33 each on Sep 01. An amount of $9,203 was transacted.
Valuation Metrics
Karyopharm Therapeutics Inc (KPTI) stock’s beta is -0.02. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.07.
Financial Health
The quick ratio of Karyopharm Therapeutics Inc for the three months ended June 29 was 4.88, and the current ratio was 4.94, indicating that the company is able to meet its debt obligations. Karyopharm Therapeutics Inc’s EBITDA margin for the year ending June 29 is -90.14%, while its operating margin for the same period stands at -85.74%. Its gross profit as reported stood at $151.86 million compared to revenue of $157.07 million.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$32.63 million in the quarter, while revenues of -$34.13 million were shrunk -50.35%. The analyst consensus anticipated Karyopharm Therapeutics Inc’s latest quarter earnings to come in at -$0.34 per share, but it turned out to be -$0.29, a 14.70% surprise. For the quarter, EBITDA amounted to -$30.31 million. Shareholders own equity worth $114.36 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Karyopharm Therapeutics Inc (KPTI) price momentum. RSI 9-day as of the close on 27 September was 60.43%, suggesting the stock is Neutral, with historical volatility in this time frame at 91.84%.
As of today, KPTI’s price is $1.2510 +15.13% or $0.1800 from its 5-day moving average. KPTI is currently trading +0.74% higher than its 20-day SMA and -50.54% lower than its 100-day SMA. However, the stock’s current price level is -8.05% below the SMA50 and -70.15% below the SMA200.
The stochastic %K and %D were 57.97% and 41.71%, respectively, and the average true range (ATR) was 0.1283. With the 14-day stochastic at 81.25% and the average true range at 0.1236, the RSI (14) stands at 53.17%. The stock has reached 0.0644 on the 9-day MACD Oscillator while the 14-day reading was at 0.0532.
Analyst Ratings
Piper Sandler launched coverage on Karyopharm Therapeutics Inc (NASDAQ: KPTI) in its analyst report released on January 19, 2023. The firm assigned the stock an Overweight rating.
